Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease.

× No keyword cloud information.

14 in total

Review 1. The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.

Authors: Anna M Barron; Giuseppe Verdile; Ralph N Martins
Journal: Endocrine Date: 2006-04 Impact factor: 3.633

2. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors: Daniel D Christensen
Journal: Prim Care Companion J Clin Psychiatry Date: 2007

3. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors: Gregory Hook; Vivian Hook; Mark Kindy
Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472

Review 4. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease.

Authors: Vivian Hook; Lydiane Funkelstein; Jill Wegrzyn; Steven Bark; Mark Kindy; Gregory Hook
Journal: Biochim Biophys Acta Date: 2011-09-08

5. Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters.

Authors: Thomas Toneff; Lydiane Funkelstein; Charles Mosier; Armen Abagyan; Michael Ziegler; Vivian Hook
Journal: Peptides Date: 2013-06-06 Impact factor: 3.750

Review 6. Brain activation of SIRT1: role in neuropathology.

Authors: Alanna Fernandes Paraíso; Keila Lopes Mendes; Sergio Henrique Sousa Santos
Journal: Mol Neurobiol Date: 2013-04-25 Impact factor: 5.590

7. Preventing formation of reticulon 3 immunoreactive dystrophic neurites improves cognitive function in mice.

Authors: Qi Shi; Marguerite Prior; Xiangdong Zhou; Xiaoying Tang; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal: J Neurosci Date: 2013-02-13 Impact factor: 6.167

8. Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic.

Authors: Gregory Hook; Jin Yu; Thomas Toneff; Mark Kindy; Vivian Hook
Journal: J Alzheimers Dis Date: 2014 Impact factor: 4.472

9. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein.

Authors: Vivian Y H Hook; Mark Kindy; Thomas Reinheckel; Christoph Peters; Gregory Hook
Journal: Biochem Biophys Res Commun Date: 2009-06-06 Impact factor: 3.575

Review 10. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease.

Authors: Vivian Hook; Israel Schechter; Hans-Ulrich Demuth; Gregory Hook
Journal: Biol Chem Date: 2008-08 Impact factor: 3.915